Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States |
| gptkbp:associatedWith |
Reduced risk of certain cancers
Improved fertility in women with PCOS Reduced risk of cardiovascular events |
| gptkbp:availableIn |
Generic_drug
|
| gptkbp:brand |
gptkb:Riomet
Fortamet Glucophage |
| gptkbp:chemicalFormula |
C4H11N5
|
| gptkbp:clinicalTrials |
Phase IV
Phase III |
| gptkbp:commonName |
500 mg to 2000 mg daily
|
| gptkbp:contraindication |
Severe renal impairment
Acute or chronic metabolic acidosis |
| gptkbp:enhances |
Peripheral glucose uptake
Glycogen_synthesis |
| gptkbp:formulation |
Liquid
Tablet |
| gptkbp:gestationPeriod |
Category B
|
| gptkbp:hasMuseum |
Generally safe
|
| https://www.w3.org/2000/01/rdf-schema#label |
Metformin
|
| gptkbp:impact |
May lower cholesterol levels
|
| gptkbp:influenceOn |
Lowers blood sugar levels
|
| gptkbp:influences |
Gut microbiota
|
| gptkbp:interactsWith |
Alcohol
Iodinated contrast media |
| gptkbp:isActiveIn |
Gluconeogenesis
Glucose absorption |
| gptkbp:isRecognizedFor |
Heart failure
Severe liver disease Pregnant women |
| gptkbp:isUsedFor |
Insulin
DPP-4 inhibitors SGLT2 inhibitors Sulfonylureas |
| gptkbp:locatedIn |
1922
|
| gptkbp:marketedAs |
Various pharmaceutical companies
|
| gptkbp:notableFeature |
gptkb:Glucophage_XR
Glumetza Riomet ER |
| gptkbp:operates_in |
A10BA02
|
| gptkbp:patentExpiration |
2020
|
| gptkbp:providesGuidelinesFor |
Polycystic ovary syndrome
|
| gptkbp:researchAreas |
Aging
Cancer prevention Diabetes management |
| gptkbp:route |
Oral
|
| gptkbp:sideEffect |
Vitamin B12 deficiency
Gastrointestinal upset Lactic acidosis |
| gptkbp:storage |
Room temperature
|
| gptkbp:triggerType |
Decreases hepatic glucose production
Increases insulin sensitivity |
| gptkbp:usedFor |
Type 2 diabetes
|
| gptkbp:weight |
Weight loss
|